Astellas Pharma Gmbh

Cytokinetics, Inc.

Toshio Kurosaki

Bradley Paul Morgan

Pu-Ping Lu

Scott E Collibee

Susumu Yamaki

Kazuyuki Tsuchiya

Wenyue Wang

Ikumi Kuriwaki

Takuya Makino

Ryuichi Sekioka

Eriko Honjo

Naoto Katoh

Yuka Koizumi

Chris Evans

Makoto Yamasaki

Hiroshi Shibata

Shigeru Yoshida

Yuki Sawada

Yuji Koga

Kenji Negoro

Takehiko Ohkawa

Tsubasa Watanabe

Akio Kuroda

Takatoshi Soga

Yasuhiro Yonetoku

Kazuhiko Ohne

Ichiro Shima

Shunichiro Hachiya

Norio Asai

Takeshi Hanazawa

Kei Ohnuki

Eisuke Nozawa

Fumiyoshi Iwasaki

Ryo Mizoguchi

Hiroki Ishioka

Aiko Wada

Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X, X, R, R, R, R, R, and Rare as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Bicyclic 1,4-diazepanones and therapeutic uses thereof

Provided herein are compounds of formula (1): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X, X, R, R, R, R, R, and Rare as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

[Problem] A pharmaceutical composition for treating or preventing various cardiovascular diseases, which have sGC activities based on improvement of cGMP signals, is provided. [Means for Solution] It was found that imidazo[1,2-a]pyridine compounds having a carbamoyl group at the 3-position and a particular cyclic group at the 8-position via a methyleneoxy group, or a salt thereof have sGC activation, and are useful as active ingredients of pharmaceutical compositions for treating or preventing various sGC-related cardiovascular diseases, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension, thereby completing the present invention.

Imidazopyridine compounds

A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.

Oxadiazolidinedione compound

A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein

2-cyanopyrrolidinecarboxamide compound

Growing community of inventors

Tokyo, Japan

Toshio Kurosaki